Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care

• Status: Completed
• Trial end date: 2019-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look at the long term safety profile of Orfadin treatment in patients suffering from hereditary tyrosinemia type 1 (HT-1). Patients included in the study will use Orfadin according to normal clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Orphan Biovitrum
• Treatments: Nitisinone

Criteria

Inclusion Criteria:

• All HT-1 patients receiving Orfadin treatment are eligible for entry.

Exclusion Criteria:

• No exclusion criteria